We’re witnessing a renaissance in cytokine targeting,” says Dr. Emily Rhodes, immunologist at the Stanford Institute for ...

All were receiving TNF inhibitors and were in remission or had low disease activity, defined as a DAS28 of3.2 or less. To determine the predictive value of serum calprotectin, TNF inhibitor trough ...

We’re not intending to capture all possible patients, but those we think would make the best trial candidates so that we can ...

The mechanisms governing immune-related adverse events resulting from checkpoint inhibition therapy for cancer remain a ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

Drug Farm, a private biotechnology company utilizing genetics and artificial intelligence technologies to discover and develop innovative, immune-modulating therapies, today announced positive results ...

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami ...

Absci has entered the clinic with its AI-designed antibody, dosing first volunteers in a trial targeting TL1A for ...

Patients with LVV and IBD present with distinct clinical characteristics, including earlier onset and more severe vascular involvement.

Study suggests gasdermin D inhibition may protect mice by blocking release of cellular contents into the extracellular ...

Dr Ray O’Connor takes a look at the latest clinical articles on rheumatoid arthritis – and how its management has been so ...